Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bjc.2015.261 http://scihub22266oqcxt.onion/10.1038/bjc.2015.261 C4647688!4647688!26196184     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Cancer 2015 ; 113 (4): 574-84 Nephropedia Template TP {{tp|p=26196184|t=2015. Targeting LKB1 in cancer ? exposing and exploiting vulnerabilities |pdf=|usr=}}{{26196184}} gab.com Text Targeting LKB1 in cancer exposing and exploiting vulnerabilities JO: Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=26196184 #FOAvip The LKB1 tumour suppressor is a serine/threonine kinase that functions as master regulator of cell growth, metabolism, survival and polarity. LKB1 is frequently mutated in human cancers and research spanning the last two decades have begun decoding the cellular pathways deregulated following LKB1 inactivation. This work has led to the identification of vulnerabilities present in LKB1-deficient tumour cells. Pre-clinical studies have now identified therapeutic strategies targeting this subset of tumours that promise to benefit this large patient population harbouring LKB1 mutations. Here, we review the current efforts that are underway to translate pre-clinical discovery of therapeutic strategies targeting LKB1 mutant cancers into clinical practice. Twit Text FOAVip Targeting LKB1 in cancer exposing and exploiting vulnerabilities ????Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=26196184 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26196184 #FOAvip English Wikipedia <ref>{{Cite pmid|26196184}}</ref> Targeting LKB1 in cancer ? exposing and exploiting vulnerabilities #MMPMID26196184 Momcilovic M; Shackelford DB Br J Cancer 2015[Aug]; 113 (4): 574-84 PMID26196184show ga The LKB1 tumour suppressor is a serine/threonine kinase that functions as master regulator of cell growth, metabolism, survival and polarity. LKB1 is frequently mutated in human cancers and research spanning the last two decades have begun decoding the cellular pathways deregulated following LKB1 inactivation. This work has led to the identification of vulnerabilities present in LKB1-deficient tumour cells. Pre-clinical studies have now identified therapeutic strategies targeting this subset of tumours that promise to benefit this large patient population harbouring LKB1 mutations. Here, we review the current efforts that are underway to translate pre-clinical discovery of therapeutic strategies targeting LKB1 mutant cancers into clinical practice. äTargeting LKB1 in cancer ? exposing and exploiting vulnerabilities (epmc).pdf DeepDyve Pubget Overpricing